This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Amgen, Horizon Therapeutics convince US FTC of behavioral remedy with extensive prior approval requirement to settle challenge to their deal

By Flavia Fortes ( September 1, 2023, 15:02 GMT | Insight) -- Amgen and Horizon Therapeutics have convinced the Federal Trade Commission to accept behavioral remedies to settle the agency’s challenge to their $27.8 billion transaction following the promise of more commitments, including extensive prior approval requirements. Amgen and Horizon Therapeutics have convinced the Federal Trade Commission to accept behavioral remedies to settle the agency’s challenge to their $27.8 billion transaction following the promise of more commitments, including extensive prior approval requirements....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login